AnaptysBio Inc. (0HFQ)
Market Closed
16 Jul, 15:27
LSE 
$
54. 86
-1.5
-2.6615%
$
- Market Cap
- P/E Ratio
- Div Yield
817 Volume
-6.06 Eps
$ 56.36
Previous Close Want to track 0HFQ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
0HFQ closed yesterday lower at $54.86, a decrease of -2.6615% from Wednesday's close, completing a monthly decrease of -17.0171% or -$11.25. Over the past 12 months, 0HFQ stock gained 13.6288%.
0HFQ is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0.93%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
0HFQ Chart
AnaptysBio Inc. (0HFQ) FAQ
What is the stock price today?
The current price is $54.86.
On which exchange is it traded?
AnaptysBio Inc. is listed on LSE.
What is its stock symbol?
The ticker symbol is 0HFQ.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has AnaptysBio Inc. ever had a stock split?
No, there has never been a stock split.
AnaptysBio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Daniel R. Faga CEO | LSE Exchange | 032724106 CUSIP |
| DE Country | 104 Employees | - Last Dividend | - Last Split | 26 Jan 2017 IPO Date |
Overview
AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of innovative immunology therapeutics to transform the lives of patients battling autoimmune and inflammatory diseases. Based in San Diego, California, the company has been at the forefront of immunological research since its incorporation in 2005. Originally known as Anaptys Biosciences, Inc., it underwent a name change in July 2006 to better reflect its evolving focus and mission. AnaptysBio sustains its growth and innovation through strategic collaborations, notably with GlaxoSmithKline, Inc., to push the boundaries of antibody therapeutics and deliver groundbreaking treatments to patients in need.
Products and Services
- Rosnilimab - An innovative IgG1 antibody designed to target PD-1+ T cells. By either agonizing or depleting these cells, Rosnilimab has the potential to broadly impact the pathogenic drivers behind a variety of autoimmune and inflammatory diseases, presenting a new avenue for treatment.
- ANB032 - This non-depleting antibody specifically binds to the BTLA checkpoint receptor. Its mechanism involves the inhibition of activated T cell proliferation, targeting the fundamental process behind inflammatory responses and offering a novel approach to suppressing disease activity.
- ANB033 - A cutting-edge anti-CD122 antagonist antibody focusing on the shared common beta subunit of the receptors for IL-15 and IL-2. By targeting this pathway, ANB033 has the potential to modulate the immune response in a manner conducive to treating various autoimmune conditions.
- ANB101 - This BDCA2 modulator antibody is specifically developed to target plasmacytoid dendritic cells (pDCs), which play a significant role in the pathogenesis of several autoimmune diseases. Through its action, ANB101 aims to offer a targeted treatment approach, minimizing the unwanted systemic effects.
- Imsidolimab - An antibody that inhibits the interleukin-36 receptor, currently in Phase 3 development for the treatment of generalized pustular psoriasis. Imsidolimab represents AnaptysBio’s commitment to addressing unmet medical needs by targeting specific pathways implicated in severe inflammatory conditions.
Contact Information
Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121-5801
Phone: 858 362 6295
Website: https://www.anaptysbio.com
